Purpose Gefitinib and erlotinib are small molecules that selectively inhibit epidermal growth
factor receptor (EGFR) tyrosine kinase activity. When these drugs were introduced into the …

Purpose This phase III, multicenter, randomized, placebo-controlled trial assessed the
efficacy and safety of sorafenib, an oral multikinase inhibitor, in combination with carboplatin …

Cancer chemotherapy is in evolution from non-specific cytotoxic drugs that damage both
tumour and normal cells to more specific agents and immunotherapy approaches. Targeted …

Purpose The phase III Iressa Survival Evaluation in Lung Cancer (ISEL) trial compared
gefitinib with placebo in 1,692 patients with refractory advanced non–small-cell lung cancer …

Abstract Background Cyclin-dependent kinases (CDKs) regulate cell proliferation and
coordinate the cell cycle checkpoint response to DNA damage. Although inhibitors with …

Systemic therapy improves the survival and quality of life of patients with advanced stage
non-small cell lung cancer (NSCLC). Several new therapeutic options have emerged for …

The success of molecular targeted therapy in cancer may depend on the selection of
appropriate tumor types whose survival depends on the drug target, so-called “oncogene …

Silencing of genes by aberrant promoter hypermethylation is now recognized as a crucial
component in cancer initiation and progression. Highly sensitive assays have been …

Purpose: Epidermal growth factor receptor (EGFR) is commonly overexpressed in lung
cancer. Cetuximab is a chimeric mouse-human antibody targeted against EGFR. Compared …

Purpose To evaluate the effect of BLP25 liposome vaccine (L-BLP25) on survival and
toxicity in patients with stage IIIB and IV non–small-cell lung cancer (NSCLC). Secondary …